Project Grant R44CA306475
Award Date 9/8/25
Completion Date 8/31/26
Dollars Obligated $407K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Van Nuys, CA 91423, USA
Similar Awards
- This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports the development of a novel, targeted small molecule inhibitor called TRE-515 by Trethera Corp, a clinical-stage biopharmaceutical company based in California. The $1,150,000 award will fund preclinical studies to evaluate TRE-515, which targets the deoxycytidine kinase (DCK) enzyme, as a potential combination therapy to prevent the DCK-mediated resistance mechanism in...
- The National Cancer Institute awarded a $269,280 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to Cold Spring Harbor Laboratory, a non-profit research institution. The grant supports the development of a novel targeted approach for K-RAS(G12C) mutation-driven cancers. The project aims to create prodrug molecules that can selectively degrade the K-RAS(G12C) protein and release cytotoxic polypharmaceuticals to concurrently target multiple pathways. The key...
- This Project Grant award, valued at $411,152, was provided by the National Cancer Institute under the Cancer Treatment Research federal grant program (CFDA 93.395). The grant supports research at Duke University to identify and validate non-covalent interacting proteins of mutant KRAS inhibitors, which are critical for developing effective therapies for lung, pancreatic, and colorectal cancers driven by oncogenic KRAS mutations. The research aims to utilize mass spectrometry-based proteomics...
- This $607,849 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is funding research at Weill Medical College of Cornell University to investigate mechanisms of genetic and non-genetic resistance to KRAS inhibitor drugs for the treatment of lung and colorectal cancers. The research aims to define how cancer cells can develop resistance to KRAS-targeted therapies, including through inflammatory gene expression pathways. The project will...
- This Project Grant award of $435,827, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research at New York University School of Medicine to investigate methods for enhancing the effectiveness of KRAS inhibitor cancer therapies. The research aims to identify synthetic lethal genetic interactions that could be leveraged to improve outcomes for patients with KRAS-mutated cancers, which are common in lung, colorectal, and pancreatic...
- The National Cancer Institute (NCI) awarded a $405,599 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Think Therapeutics, Inc. to advance next-generation cancer vaccines with superior immunogenic payloads for KRAS mutations. The project aims to characterize the immunogenicity of novel vaccine products and evaluate the cross-reactivity of T cell responses that recognize tumor-presented neoepitopes, leveraging the development of programmable mRNA vaccine...
- The National Cancer Institute (NCI) awarded a $602,881 Project Grant under CFDA 93.395, the Cancer Treatment Research program, to Duke University. The grant supports research to develop novel immunotherapies using engineered IgG antibodies that can penetrate tumor cells and neutralize oncogenic mutations, such as KRAS. The research aims to translate these tumor cell-penetrating antibodies into the clinic, overcoming challenges associated with the low yield and half-life of previous recombinant...
- This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $433,256 to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The funding supports research to identify novel targets and develop lead compounds to overcome resistance to KRAS inhibitors for lung, colon, and other cancers. The project leverages fragment-based chemoproteomics approaches to probe biological target...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $703,410.00 to New York University School of Medicine to conduct research on the adeno-to-squamous transition in non-small cell lung cancer. The research aims to identify chromatin regulators that drive this cellular adaptation, which enables resistance to targeted KRAS inhibitor therapy. The award began on January 16, 2025 and is scheduled to run through December 31, 2029....
- The federal Cooperative Agreement award for "Next Generation T Cell Therapies for Mutant KRAS Solid Tumors" was provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research). The $2,238,704 award supports the early-stage clinical testing of a novel T cell receptor (TCR1020) therapy targeting the KRAS G12V mutation in solid tumors. The project aims to develop genetically modified T cells to overcome resistance mechanisms and promote durable tumor regression. Key...